Status Topic selection
Technology type Medicine
Decision Not selected
Reason for decision Not eligible for Health Technology Evaluation guidance
Further information Decision makers have concluded that a new technology appraisal is not necessary for this licence extension. The guidance in development for Efgartigimod for treating generalised myasthenia gravis [ID4003] will consider the sub-cut formulation, but there will not be a specific recommendation on it, as per standard NICE practice. Please see Section 6.2.1 of the Topic Selection Manual states that: Medicines that meet the eligibility criteria will be selected, except when there is a clear rationale not to do so. For example, when: changes to the dose, formulation or administration will not significantly affect the clinical and cost effectiveness of the medicine.
ID number 11835

Project Team

Project lead Abigail Stephens

Email enquiries

For further information on how we select topics for development, please see our page about topic selection